Mpox Information for Providers - NYC Health

Health

Promoting and Protecting the City's Health


Reporting and ServicesHealth TopicsResourcesEmergency Prep

By Disease or Condition
Immunizations
Alcohol and Drug Use
Smoking and Tobacco Use
Sexual and Reproductive Health
Infectious Diseases
Health Care-Associated Infections
Children and Adolescents
Immigrant Health

By Disease or Condition

Immunizations

Alcohol and Drug Use

Smoking and Tobacco Use

Sexual and Reproductive Health

Infectious Diseases

Health Care-Associated Infections

Children and Adolescents

Immigrant Health


Mpox: Information for Providers

Go to: Clinical Information | Management and Treatment | Equity | Vaccination | Testing | Infection Control

Updates on Mpox in New York City

In NYC, there have been increases in mpox cases since October 2023, although the overall number of mpox cases remains low compared to the 2022 outbreak.

As of April 1, 2024, the JYNNEOSTM vaccine has begun transition to the commercial market. Access to no-cost federal supplies is available until early summer 2024. Within a few months of commercialization, the JYNNEOS vaccine will most likely be made available through the Vaccines for Children (VFC) Program (for eligible adolescents).

The New York City Health Department recently released a Health Advisory Network update (PDF) including information about an outbreak of Clade I mpox cases caused by human-to-human transmission in the Democratic Republic of the Congo, which has been observed to be more transmissible and to cause more severe infections. Isolation, vaccination and treatment strategies used for Clade II infections (those seen in the United States so far) are expected to be effective for Clade I infections. If a medical provider suspects Clade I mpox, they should call the Provider Access Line (866-692-3641).

See further guidance under Patient Management and Treatment.

STOMP Clinical Study Information

Providers should inform patients with mpox about the Study of Tecovirimat for Mpox (STOMP) for their voluntary participation. Multiple study sites are available in NYC and remote enrollment across the U.S. is available. Access to oral tecovirimat is also available for patients with mpox who meet eligibility criteria (such as patients who have severe disease or involvement of anatomic areas that might result in serious sequelae or are at high risk for severe disease) under CDC’s expanded access protocol in accordance with CDC’s Guidance for Tecovirimat Use.

Dear Colleague Letter: Update on STOMP Trial and Tecovirimat Availability (PDF, December 27, 2024)

Mpox Care for Minors

In New York State, minors can receive mpox testing, treatment and vaccination without a parent’s consent.

NYC Health Advisories and Provider Letters

2023

Health Advisory #25: CDC Advisory Update on Mpox Caused by Human-to-Human Transmission of Mpox Virus with Geographic Spread in the Democratic Republic of the Congo (PDF, December 13)

2022

Health Advisory #30: CDC Advisory Update on Managing Mpox in Patients Receiving Therapeutics (PDF, November 22)

Letter to Providers: Considerations for MPV and Pregnant, Recently Pregnant and Breastfeeding Patients (PDF, October 17)

Health Advisory #25: CDC Advisory Severe Manifestations of Mpox Among People Who Are Immunocompromised Due to HIV or Other Conditions (PDF, October 5)

Clinical Information

During the 2022 outbreak, including in NYC, most people diagnosed with mpox have been men who have sex with men. Transmission has primarily occurred through sex and other intimate contact. However, anyone can get mpox, so consider this diagnosis in all patients with consistent signs or symptoms.

The incubation period is typically three days to three weeks, and illness typically last two to four weeks.

Lesions may:

Be solitary or emerge in groups

Involve both skin and mucous membranes

Be most prominent in the anogenital area or mouth

Information on transmission and clinical presentation, including photos of mpox lesions, are available on CDC’s Clinical Recognition and Clinician FAQ webpages.

Lesions can be very itchy and painful, especially those in the oral, anogenital, or rectal areas, and may interfere with eating, urination, and/or defecation. Supportive care, including pain management, should be offered to all people with mpox.

Advise patients with mpox to follow precautions until all the scabs that form on the skin have fallen off and a fresh layer of skin has formed. This can take two to four weeks from when the lesions first appear.

Refer patients to the Health Department’s Mpox: What to Do When Sick page for guidance and CDC’s Advice for Mpox Patients to Reduce Transmission.

Patient Management and Treatment

Most people diagnosed with mpox have not required hospitalization. However, severe illness and rare deaths have occurred among people with mpox and severe immunocompromise, most often due to advanced HIV. Test all sexually active people being evaluated for mpox for HIV (including acute HIV infection) if their HIV status is unknown, and for other sexually transmitted infections, including syphilis, genital herpes, gonorrhea, and chlamydia.

Refer to CDC Clinical Guidance for information on managing patients with mpox, including tailored guidance for the following populations:

People with Severe Manifestations of Mpox

People with HIV

People Who are Pregnant or Breastfeeding

Children and Adolescents

CDC guidance on treatment and pain management:

CDC: Treatment Information for Healthcare Professionals

CDC: Considerations for Pain Management in People with Mpox

Providers may contact the CDC Clinical Escalations team at eocevent482@cdc.gov to discuss clinical management strategies, including the use of tecovirimat, vaccinia immune globulin intravenous (VIGIV), brincidofovir and cidofovir. For immediate consultation regarding hospitalized patients with or who are at risk for severe manifestations, call the Clinical Escalations team directly at 770-488-7100.

Antiviral Treatment

Providers should inform patients with mpox about the Study of Tecovirimat for Mpox (STOMP) for their voluntary participation. Multiple study sites are available in NYC and remote enrollment across the U.S. is available. Access to oral tecovirimat is also available for patients with mpox who meet eligibility criteria (such as patients who have severe disease or involvement of anatomic areas that might result in serious sequelae or are at high risk for severe disease) under CDC’s expanded access protocol in accordance with CDC’s Guidance for Tecovirimat Use.

To avoid progression to severe disease, tecovirimat should be started immediately for patients with a CD4 <200 or who are otherwise immunocompromised, are new diagnosis of HIV, or living with HIV but have an unknown immune status at the time of mpox evaluation; do not wait until receipt of laboratory results (e.g., viral load and CD4 count) in case the patient is at risk for progressing to severe mpox disease during that time. Strongly consider prolonged tecovirimat treatment until patient has achieved immune reconstitution. For patients newly diagnosed with HIV (based on either a lab test or a point-of-care HIV test), immediately start HIV treatment. For patients with progressive or non-resolving lesions while on tecovirimat, providers should consult the CDC Emergency Operations Center at (7790) 488-7100 or poxvirus@cdc.gov to discuss additional treatment options and resistance testing.

Consider antiviral treatment of mpox infection for people with:

Severe disease, including confluent lesions or lesions in anatomical areas at special risk of scarring or stricture (e.g., near or involving the eye, mouth, rectum or urethra).

Illness complications including proctitis (particularly with tenesmus, challenges in pain control or rectal bleeding), urethritis and phimosis.

Increased risk for progression to severe disease, including people who are immunocompromised, pregnant or breastfeeding, have atypic dermatitis or other exfoliative skin conditions, and children.

Tecovirimat is provided at no cost by the federal government. Patients should not be charged for the medicine, but providers may bill for the encounter.

To prescribe tecovirimat under CDC’s expanded access protocol to eligible patients refer to: CDC: Information for Healthcare Providers: Tecovirimat (TPOXX) for Treatment of Mpox. Providers can now register as a participating site/provider under the CDC-held EA-IND and submit forms to the CDC through the online Tecovirimat (TPOXX) IND Registry.

At this time outpatient tecovirimat can only be prescribed through Pharmex Pharmacy, who will deliver to the patient’s preferred address at no cost within New York City.

Pharmex Pharmacy Inc.

142-08 Rockaway Blvd.

Jamaica, NY 11436

Phone 917-444-1985

Fax 718-504-4811

If your e-prescription system does not have tecovirimat listed, prescriptions are accepted by phone or fax.

Prescriptions confirmed by 3 p.m. on weekdays, or by noon on Saturdays will be delivered the same day. Prescriptions sent after noon on Saturday will be delivered on Monday.

Equity in Care

Black and Latino men who have sex with men, as well as transgender and gender non-conforming people, may have less equitable experiences with health care.

See data on mpox cases from the 2022 outbreak.

Providers should ensure that everyone, especially patients who are low-income, Black, or Latino, receives equitable access to testing and proper care that includes access to vaccines, antiviral treatment, pain management, and mental health care.

We encourage providers and their staff to use trainings and other resources to help them counter their own implicit biases.

Vaccination

The JYNNEOS vaccine is available in NYC to anyone who considers themselves to be at risk for mpox through sex or other intimate contact. Vaccination is strongly recommended for men who have sex with men, people with HIV, and other groups that may have an elevated risk of exposure.

The standard regimen for JYNNEOS is two doses administered subcutaneously 28 days apart. Peak immunity from vaccination is expected two weeks after the second dose. The estimated vaccine effectiveness of JYNNEOS for preventing mpox disease has ranged from 66-89% for the two-dose series.

People who are identified as close contacts of a person with mpox should get two doses of the JYNNEOS vaccine as post-exposure prophylaxis (PEP), particularly if they are immunocompromised due to HIV or other conditions. Vaccination within four days of exposure provides the best chance to prevent mpox, and vaccination within five to 14 days of exposure may reduce symptoms for people who go on to develop mpox illness.

For more information, see CDC: Mpox Vaccine Information for Healthcare Professionals.

Testing

Submit specimens for mpox testing to a participating commercial laboratory, including LabCorp, Mayo Clinic Laboratories, Aegis Science, Sonic Healthcare or Quest Diagnostics, or to a health care system laboratory that has been approved to conduct mpox testing by New York State. Refer to the lab's specimen collection and submission guidance.

Testing is also available through the NYC Public Health Laboratory if prior approval is obtained by calling the Provider Access Line at 866-692-3641. See Mpox Testing at the NYC Public Health Lab (PDF) for specimen collection and handling guidance. Providers must give mpox test results to patients. The NYC Health Department cannot provide test results to patients, even when testing is done at the Public Health Lab.

People with suspicious lesions should be asked about recent travel and if they visited the Democratic Republic of the Congo in the previous three weeks of symptom onset. For clade I testing and treatment of a suspected mpox case patient who reports travel to the Democratic Republic of the Congo, New York City providers should call the Provider Access Line (866-692-3641).

We encourage providers to be judicious about ordering and interpreting results of mpox testing for patients who have a very low risk for exposure. False-positive test results may lead to unnecessary treatment or isolation. Consider other diagnoses (including hand, foot, and mouth disease, molluscum contagiosum, acne and folliculitis) in people with a rash who are not sexually active and have no known household or other exposure to someone with mpox.

Infection Prevention and Control in Health Care Settings

New York State: Mpox Cases in Healthcare Delivery Settings (PDF, July 25, 2022)

CDC: Infection Prevention and Control of Mpox in Healthcare Settings

Past Webinars

2022

LGBTQ Cultural Competency Update for MPV Response (October 19)

Slides (PDF)

Mpox/MPV Vaccination and Care for Adolescents: Access and Best Practices (October 27)

Slides (PDF)

Dermatologic Considerations for Mpox among People of Color (September 29)

Slides (PDF)